Amy Abernethy now has a whole new set of tools to tap into as she scales up the clinical trial management platform at Verily.

The life sciences outfit — now officially a subsidiary of Alphabet on equal footing with Google — has acquired SignalPath for an undisclosed amount, giving it access to a system of digital solutions that make it easier to run clinical trials, and promise to simultaneously boost quality and efficiency.

BioVision has supplied Abcam with research tools since 1999, and now the two are making it official as part of a merger unveiled Monday.

Abcam will buyout BioVision as part of a $340 million acquisition deal to bring aboard the supplier’s biochemical and cell-based assays for biological research, as well as recombinant proteins, antibodies and enzymes.

The deal will give Abcam control of BioVision’s portfolio and allow for both the expansion of research existing areas of focus such as oncology, neuroscience and epigenetics and preparation to expand into new products. As a part of the deal, Abcam will develop and supply products and services to NKY, the previous owner of BioVision and receive support for ongoing development and commercialization of in vitro diagnostic products.

India is getting a manufacturing boost that will add the capacity to produce another 1 billion injectables.

Recipharm announced the construction of a new fill-finish facility in Uttarakhand, near Dehradun, in collaboration with the Sobti family. The development is the latest move in a partnership with the family, which began in 2019 after Recipharm invested in Nichepharm.

The site will up Recipharm’s sterile fill-finish service to complement already existing locations in France, Germany and Italy. The project’s next step is to gain authorization from European regulators.

For the second time in less than six months, Catalent will upgrade its sleek new facility in Anagni, Italy, this time to add biologics drug substance manufacturing capabilities to support an increase in demand.

Two new 2,000 liter single-use bioreactors with new manufacturing suites will support early-phase clinical development and late-stage commercial transfers, the company said in a press release, as well as space for another six bioreactors to be added in the future. The project is expected to add 100 new employees, and it should be operational in April 2023.

It’s been a quiet few weeks for one of the busiest CDMOs out there, but Catalent broke its lull with the announcement of two partnerships this week.

Curtana Pharmaceuticals, an Austin, TX-based preclinical company, announced a partnership with the manufacturer Thursday to make CT-179, its drug therapy for glioblastoma, medulloblastoma and other brain cancers.

CT-179 is a selective small molecule inhibitor of LIG2, a transcription factor essential to early brain development but often not expressed in adult brain cells. The development will take place at Catalent’s San Diego facility.

Generate Life Sciences is the largest private newborn stem cell biorepository, and with the announcement of its own in-house manufacturing facility, the company is looking to grow its regenerative medicine pipeline.

Generate has established a facility in La Jolla, CA, to provide end-to-end manufacturing for newborn stem cell biologics. The site will allow Generate to evolve as it adds a personalized therapeutics developer to its current business model. The new site has been designed to harness mesenchymal stem cells from the tissue of the umbilical cord.

The team at Cellares hopes that its Cell Shuttle is the future of end-to-end cell therapy manufacturing. On Wednesday, the company announced that one more company has signed up to work alongside it.

Poseida has signed on to provide therapies for the Cell Shuttle, a portable factory Cellares hopes will disrupt the expensive and logistically complicated cell therapy manufacturing process. The company is the third to ink a deal with Cellares, which is based out of South San Francisco, CA. Cellares has already has been collaborating with PACT Pharma and the Fred Hutchinson Cancer Research Center.

From India to NJ, the core of the FDA’s instructions to Lupin subsidiary Novel Laboratories were the same: establish proper cleaning and process validation guidelines at your manufacturing sites. And after failing to do so for the third time in four years, the company has received a warning letter.

Drug residue on tablet presses and a failure to validate the manufacturing process after equipment changes were just two of the issues raised by the FDA after an inspection of a Novel Laboratories plant that led to the June 11 letter.